New pill shows promise for Tough-to-Treat blood cancers
NCT ID NCT03162536
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times
Summary
This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants take the drug daily and are monitored for side effects and cancer response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute ( Site 0225)
Denver, Colorado, 80218, United States
-
Duke Cancer Center ( Site 0067)
Durham, North Carolina, 27710, United States
-
Mayo Clinic - Rochester ( Site 0138)
Rochester, Minnesota, 58905, United States
-
Mayo Clinic Hospital ( Site 0140)
Scottsdale, Arizona, 85259, United States
-
Tennessee Oncology, PLLC ( Site 0020)
Nashville, Tennessee, 37203, United States
-
The Ohio State University Wexner Medical Center ( Site 0056)
Columbus, Ohio, 43210, United States
-
UCLA Hematology & Oncology ( Site 0017)
Los Angeles, California, 90095, United States
-
UT Southwestern Medical Center ( Site 0116)
Dallas, Texas, 75390-8562, United States
-
University of Michigan ( Site 0018)
Ann Arbor, Michigan, 48109, United States
-
University of Utah, Huntsman Cancer Institute ( Site 0122)
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.